WO2008157791A3 - Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones - Google Patents

Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones Download PDF

Info

Publication number
WO2008157791A3
WO2008157791A3 PCT/US2008/067742 US2008067742W WO2008157791A3 WO 2008157791 A3 WO2008157791 A3 WO 2008157791A3 US 2008067742 W US2008067742 W US 2008067742W WO 2008157791 A3 WO2008157791 A3 WO 2008157791A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
useful
neuronal degeneration
isothiazolopyrimidinones
Prior art date
Application number
PCT/US2008/067742
Other languages
French (fr)
Other versions
WO2008157791A2 (en
Inventor
Judith Kelleher Anderson
Original Assignee
Neuronascent, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08771642.9A priority Critical patent/EP2170340B1/en
Priority to DK08771642.9T priority patent/DK2170340T3/en
Priority to RU2010100945/15A priority patent/RU2521333C2/en
Priority to US12/664,995 priority patent/US8609840B2/en
Priority to JP2010513461A priority patent/JP2010530898A/en
Priority to CN200880021069A priority patent/CN101842100A/en
Priority to PL08771642T priority patent/PL2170340T3/en
Priority to ES08771642.9T priority patent/ES2564826T3/en
Application filed by Neuronascent, Inc. filed Critical Neuronascent, Inc.
Priority to CA2693062A priority patent/CA2693062C/en
Priority to AU2008265600A priority patent/AU2008265600B2/en
Priority to KR1020157008401A priority patent/KR101600054B1/en
Publication of WO2008157791A2 publication Critical patent/WO2008157791A2/en
Priority to IL202485A priority patent/IL202485A/en
Publication of WO2008157791A3 publication Critical patent/WO2008157791A3/en
Priority to US14/079,489 priority patent/US9096613B2/en
Priority to US14/751,403 priority patent/US9592234B2/en
Priority to IL251169A priority patent/IL251169A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

The present invention provides methods and compositions comprising compounds useful for stimulating neurogenesis. The methods and compositions comprising compounds are also useful for inhibiting neuronal degeneration. Thus, the present invention can be used in the treatment of diseases and conditions characterized by neuronal loss and reduced neurogenesis including Alzheimer's disease, stroke, traumatic brain injury, traumatic nerve injury, and depression. This invention is useful for research products including single agents or mixtures of agents to promote, proliferate, differentiate, or maintain neurons from stem or progenitor cells.
PCT/US2008/067742 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones WO2008157791A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA2693062A CA2693062C (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
DK08771642.9T DK2170340T3 (en) 2007-06-21 2008-06-20 Methods and compositions for Stimulating neurogenesis and inhibition of neuronal degeneration BY USING ISOTHIAZOLOPYRIMIDINONER
AU2008265600A AU2008265600B2 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
JP2010513461A JP2010530898A (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinone
CN200880021069A CN101842100A (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
PL08771642T PL2170340T3 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
ES08771642.9T ES2564826T3 (en) 2007-06-21 2008-06-20 Methods and compositions to stimulate neurogenesis and inhibit neuronal degeneration using isothiazolopyrimidinones
EP08771642.9A EP2170340B1 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
RU2010100945/15A RU2521333C2 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulation of neurogenesis and inhibition of neuron degeneration with using isothiazolopyrimidinones
US12/664,995 US8609840B2 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
KR1020157008401A KR101600054B1 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
IL202485A IL202485A (en) 2007-06-21 2009-12-03 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US14/079,489 US9096613B2 (en) 2007-06-21 2013-11-13 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US14/751,403 US9592234B2 (en) 2007-06-21 2015-06-26 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
IL251169A IL251169A0 (en) 2007-06-21 2017-03-14 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94552407P 2007-06-21 2007-06-21
US60/945,524 2007-06-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/664,995 A-371-Of-International US8609840B2 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US14/079,489 Division US9096613B2 (en) 2007-06-21 2013-11-13 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones

Publications (2)

Publication Number Publication Date
WO2008157791A2 WO2008157791A2 (en) 2008-12-24
WO2008157791A3 true WO2008157791A3 (en) 2009-12-30

Family

ID=40156978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/067742 WO2008157791A2 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones

Country Status (13)

Country Link
US (3) US8609840B2 (en)
EP (2) EP2170340B1 (en)
JP (4) JP2010530898A (en)
KR (2) KR101565971B1 (en)
CN (1) CN101842100A (en)
AU (1) AU2008265600B2 (en)
CA (1) CA2693062C (en)
DK (1) DK2170340T3 (en)
ES (1) ES2564826T3 (en)
IL (2) IL202485A (en)
PL (1) PL2170340T3 (en)
RU (1) RU2521333C2 (en)
WO (1) WO2008157791A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008265600B2 (en) * 2007-06-21 2013-10-31 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
WO2010019210A2 (en) 2008-08-11 2010-02-18 President And Fellows Of Harvard College Halofuginone analogs for inhibition of trna synthetases and uses thereof
RU2549441C2 (en) * 2009-09-22 2015-04-27 Ньюронасент, Инк. Methods and pharmaceutical compositions for treating down syndrome
US10155742B2 (en) 2012-01-13 2018-12-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
DK2968304T3 (en) 2013-03-14 2019-01-28 Univ Columbia 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE.
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
WO2014152018A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
CN111393434B (en) 2014-04-30 2022-11-04 哥伦比亚大学董事会 Substituted 4-phenylpiperidines, their preparation and use
RU2613765C1 (en) * 2016-01-26 2017-03-21 Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет им. М.К.Аммосова" Method for spinocerebellar ataxia treatment
US10064833B2 (en) * 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
RU2670128C2 (en) * 2016-12-16 2018-10-18 Федеральное государственное автономное образовательное учреждение высшего образования "Балтийский федеральный университет имени Иммануила Канта" (БФУ им. И. Канта) Method of genetic registration and correction of neurogenesis based on genetic constructions for transfection of neurons
RU2675111C2 (en) * 2017-03-31 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Method for stimulating neurogenesis in the hippocampus
EP3648605A1 (en) * 2017-07-03 2020-05-13 Bayer CropScience Aktiengesellschaft Novel isothiazolo-based bicycles, processes for their preparation and their use as herbicides and/or plant growth regulators
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US20070078083A1 (en) * 2005-09-07 2007-04-05 Braincells, Inc. MODULATION OF NEUORGENESIS BY HDac INHIBITION

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH588887A5 (en) 1974-07-19 1977-06-15 Battelle Memorial Institute
US4089809A (en) * 1976-03-01 1978-05-16 The United States Of America As Represented By The United States Department Of Energy Regenerable sorbent and method for removing hydrogen sulfide from hot gaseous mixtures
US4233871A (en) 1978-04-26 1980-11-18 Alessi Anthony A Notching tool
EP0032578B1 (en) 1980-01-16 1984-07-25 Hans Georg Prof. Dr. Weder Process and dialysis-installation for the preparation of bilayer-vesicles and their use
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4438253A (en) 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4532089A (en) 1984-01-14 1985-07-30 Northwestern University Method of preparing giant size liposomes
US4897269A (en) 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
JP2670680B2 (en) * 1988-02-24 1997-10-29 株式会社ビーエムジー Polylactic acid microspheres containing physiologically active substance and method for producing the same
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5820880A (en) 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
WO2000067776A1 (en) * 1999-05-11 2000-11-16 Ortho-Mcneil Pharmaceuticals, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
WO2004078758A1 (en) 2003-03-07 2004-09-16 Astrazeneca Ab Novel fused heterocycles and uses thereof
ES2351624T3 (en) 2003-05-06 2011-02-08 Ústav Experimentálni Botaniky Av Cr, V.V.I. (Institute Of Experimental Botany Academy Of Sciences Of The Czech Republic, Pro) PIRAZOLO [4,3-D] PYRIMIDINS, PROCEDURE FOR PREPARATION AND USE.
AR050921A1 (en) * 2004-08-18 2006-12-06 Astrazeneca Ab SELECTED FUSIONED HEREROCICLES AND USES OF THE SAME
AU2008265600B2 (en) * 2007-06-21 2013-10-31 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US20070078083A1 (en) * 2005-09-07 2007-04-05 Braincells, Inc. MODULATION OF NEUORGENESIS BY HDac INHIBITION

Also Published As

Publication number Publication date
CN101842100A (en) 2010-09-22
JP5850981B2 (en) 2016-02-03
JP2015163648A (en) 2015-09-10
EP3053584A1 (en) 2016-08-10
JP2017066166A (en) 2017-04-06
EP2170340A2 (en) 2010-04-07
US20140171428A1 (en) 2014-06-19
IL251169A0 (en) 2017-04-30
EP2170340A4 (en) 2010-12-08
RU2521333C2 (en) 2014-06-27
IL202485A0 (en) 2010-06-30
KR20150041668A (en) 2015-04-16
AU2008265600A1 (en) 2008-12-24
US8609840B2 (en) 2013-12-17
JP2010530898A (en) 2010-09-16
IL202485A (en) 2017-03-30
US9096613B2 (en) 2015-08-04
ES2564826T3 (en) 2016-03-29
CA2693062C (en) 2016-08-09
US9592234B2 (en) 2017-03-14
RU2010100945A (en) 2011-07-27
WO2008157791A2 (en) 2008-12-24
US20100298318A1 (en) 2010-11-25
KR101600054B1 (en) 2016-03-04
JP6081528B2 (en) 2017-02-15
AU2008265600B2 (en) 2013-10-31
DK2170340T3 (en) 2016-03-14
PL2170340T3 (en) 2016-06-30
US20160022682A1 (en) 2016-01-28
KR20100040728A (en) 2010-04-20
JP2014196308A (en) 2014-10-16
CA2693062A1 (en) 2008-12-24
EP2170340B1 (en) 2016-02-24
KR101565971B1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
WO2007035722A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2007024441A3 (en) Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof
MY159562A (en) Adipose tissue derived stromal cells for the treatment of neurological disorders
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
SG155236A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
PH12015501207A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
ATE481978T1 (en) COMPOSITIONS AND METHODS FOR TREATING HEART DISEASES
MX2009006700A (en) 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors.
MX2007007032A (en) Aminopyrimidine compounds and methods of use.
UA91895C2 (en) Thiazole compounds and methods of use
ES2354824T3 (en) PIRAZOLO [1,5-A] USEFUL PYRIMIDINS AS INHIBITORS OF KINASE PROTEINS.
WO2006044860A3 (en) Thiadiazole compounds and methods of use
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2006080952A3 (en) Improved modalities for the treatment of degenerative diseases of the retina
MX2010000351A (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders.
WO2008080045A3 (en) Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders
MX2010006748A (en) PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS.
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
WO2009067493A3 (en) 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008129023A3 (en) Oligonucleotide compositions for the treatment of alzheimer's disease
MX2018009189A (en) Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof.
MY153738A (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880021069.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08771642

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2693062

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008265600

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010513461

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 7462/CHENP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008265600

Country of ref document: AU

Date of ref document: 20080620

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107001298

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010100945

Country of ref document: RU

Ref document number: 2008771642

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12664995

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 251169

Country of ref document: IL